By Riley Stanton, CAFP Communications and Marketing Intern The manufacturers of opioid painkillers aggressively marketed their products in the 1990s, exaggerating the benefits and downplaying the risks, while simultaneously lobbying
By Sarah Martinez, CAFP Policy & Advocacy Intern In October, the U.S. Senate passed the final version of H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment
